Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATG 022

Next Previous
Drug Profile

ATG 022

Alternative Names: ATG-022; ATN-022

Latest Information Update: 02 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antengene Corporation
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis inhibitors; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Gastric cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Adenocarcinoma; Solid tumours

Most Recent Events

  • 20 Mar 2026 Phase-I/II clinical trials in Adenocarcinoma (Inoperable/Unresectable, Metastatic disease, Combination therapy) in China (Parenteral) (NCT07327229)
  • 20 Mar 2026 Antengene plans a phase III trial for Gastric cancer (Monotherapy) in 2026
  • 16 Jan 2026 Updated efficacy data from the phase I/II CLINCH trial in Gastric cancer released by Antegene Corporation

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top